HYUNDAI BIOSCIENCE CO. LTD.

As of March 31, 2026, HYUNDAI BIOSCIENCE CO. LTD. carries a market capitalization of 1.28T, placing it among publicly traded companies globally. Its enterprise value stands at 1.26T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, HYUNDAI BIOSCIENCE CO. LTD. has 96.50M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 407.77, and the price-to-book ratio stands at 11.46.

These figures are as of March 31, 2026. The EV/Sales ratio of 402.39 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.26T versus a market cap of 1.28T, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, HYUNDAI BIOSCIENCE CO. LTD. maintains a current ratio of 2.40, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.48, indicating elevated leverage, while an interest coverage ratio of -16.07 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, HYUNDAI BIOSCIENCE CO. LTD. posted a negative return on equity (ROE) of -18.56, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -15.69, reflecting losses generated across the asset base. The company generates approximately 51.36M in revenue per employee across its workforce of 61.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.18 indicates how many times HYUNDAI BIOSCIENCE CO. LTD. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, HYUNDAI BIOSCIENCE CO. LTD. recorded 2.94M in income tax expense. The company reported a pretax loss of -21.28B and -21.30B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, HYUNDAI BIOSCIENCE CO. LTD.'s stock has gained approximately 21.52% over the past 52 weeks. The 50-day moving average sits at 6,790.00, while the 200-day moving average is 9,628.10.

Over the twelve months ended March 31, 2026, HYUNDAI BIOSCIENCE CO. LTD. generated 3.13B in revenue and converted that into -21.30B in net income, yielding earnings per share of -221.54. EBITDA reached -17.18B, while operating income came in at -18.54B.

As of March 31, 2026, HYUNDAI BIOSCIENCE CO. LTD. holds 37.80B in cash and equivalents against 15.09B in total debt, resulting in a net debt position of 6.56B. Total book value stands at 111.98B, with working capital of 23.34B providing operational flexibility.

HYUNDAI BIOSCIENCE CO. LTD. produced -15.69B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -348.59M in capital expenditures, free cash flow totaled -16.03B - equivalent to -166.91 per share.

Over the twelve months ended March 31, 2026, HYUNDAI BIOSCIENCE CO. LTD. posted a gross margin of -0.55, reflecting its pricing power and cost economics. The operating margin of -591.83 and net profit margin of -679.88 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -1.25: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.38, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to HYUNDAI BIOSCIENCE CO. LTD. shareholders.

HYUNDAI BIOSCIENCE CO. LTD.'s most recent stock split took place on July 24, 2025 with a 1:2 split ratio.

As of March 31, 2026, HYUNDAI BIOSCIENCE CO. LTD. has an Altman Z-Score of 43.72, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.